Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection

References

• Beggs ML, Stevanova R. Species identification of mycobacterium avium complex isolates by a variety of molecular techniques. J Clin Microbiol. 2000;38(2):508–512.
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020;71(4):e1–e36.
   PubMed Web of Science ®Google Scholar
• Reddy VM. Mechanism of mycobacterium avium complex pathogenesis. Front Biosci. 1998;3:525–531.
   Google Scholar
• Mirsaeidi M, Machado RF, Garcia JGN, et al. Non-tuberculous mycobacterial disease mortality in the united states, 1999 – 2010 : A population-based comparative study. PLoS One. 2014;9(3):1–9.
   Web of Science ®Google Scholar
• Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 2020;11:1–12.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc. 2020;17(2):–15. 2008
   PubMed Web of Science ®Google Scholar
• Mycobacteria N, Brode SK, Marchand-austin A, et al. Pulmonary versus nonpulmonary nontuberculous mycobacterial, ontario, Canada. Emerg Infect Dis. 2017;23(11):9–12.
   Web of Science ®Google Scholar
• Moore JE, Kruijshaar ME, Ormerod LP, et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health. 2010;10(1):612.
   PubMedGoogle Scholar
• Park YS, Lee C-H, Lee S-M, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis. 2010;14(8):1069–1071.
   Google Scholar
• Morimoto K, Iwai K, Uchimura K, et al. A steady increase in non-tuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1–8.
   PubMedGoogle Scholar
• Prevots DR, Marras TK. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Koh W. Diagnosis and treatment of non-tuberculous mycobacterial lung disease. J Korean Med Sci. 2016;31: 649–659.
   Google Scholar
• Marras TK, Vinnard C, Zhang Q, et al. Relative risk of all-cause mortality in patients with non-tuberculous mycobacterial lung disease in a US managed care population. Respir Med. 2018;145:80–88.
   PubMed Web of Science ®Google Scholar
• Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18(1):206. 3;
   PubMed Web of Science ®Google Scholar
• Jr RJ W, Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276–282.
   PubMed Web of Science ®Google Scholar
• Jeong B-H, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191(1):96–103.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity : daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:0–6.
   Web of Science ®Google Scholar
• Haworth CS, Banks J, Capstick T, et al. British thoracic society guideline for the management of non- tuberculous mycobacterial pulmonary disease (NTM-PD).
   Google Scholar
• Kwak N, Park J, Kim E, et al. Treatment outcomes of mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(7):1077–1084.
   Google Scholar
• Pasipanodya JG, Ogbonna D, Deshpande D, et al. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother. 2017;72(suppl_2):i3–19.
   PubMedGoogle Scholar
• Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153(4):888–921.
   PubMed Web of Science ®Google Scholar
• Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004 Aug;126(2):566–581.
   PubMed Web of Science ®Google Scholar
• Xu H-B, Jiang R-H LL. Treatment outcomes for Mycobacterium avium complex: A systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2015;25:33.
   Google Scholar
• Van IJ, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559–565.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee JS, Kwak N, et al. Role of ethambutol and rifampicin in the treatment of mycobacterium avium complex pulmonary disease. BMC Pulm Med. 2019;19(212):1–10.
   PubMedGoogle Scholar
• Deshpande D, Srivastava S, Meek C, et al. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated mycobacterium avium infection. Antimicrob Agents Chemother. 2010;54(6):2534–2539.
   PubMed Web of Science ®Google Scholar
• Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for non-tuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9–16.
   PubMedGoogle Scholar
• Shirley M. Amikacin liposome inhalation suspension : a review in mycobacterium avium complex lung disease. Drugs. 2019;79(5):555–562.
   PubMed Web of Science ®Google Scholar
• Zhang J, Leifer F, Rose S, et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018;9:1–12.
   PubMed Web of Science ®Google Scholar
• Grayson JB, Hersh EM, Dorr RT, et al. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J Antimicrob Chemother. 1996;38(5):819–828. 1;
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med. 1976;295(14):765–770.
   PubMed Web of Science ®Google Scholar
• Bilton D, Pressler T, Isabelle F, et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (ARIKACE) compared with tobi® in cystic fibrosis patients with chronic infection due to pseudomonas aeruginosa. Pediatr Pulmonol. 2013;48:290. 1;
   Web of Science ®Google Scholar
• Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules. 2017;22(12):2267. 19;
   PubMed Web of Science ®Google Scholar
• Krause KM, Serio AW, Kane TR, et al. Aminoglycosides : an Overview. Cold Spring Harbor Perspect Med. 2016;6(6):1–18.
   Web of Science ®Google Scholar
• Polikanov YS, Aleksashin NA, Beckert B, et al. The mechanisms of action of ribosome-targeting peptide antibiotics. Front Mol Biosci. 2018;5:1–21.
   PubMed Web of Science ®Google Scholar
• Nessar R, Reyrat JM, Murray A, et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother. 2011;66(8):1719–1724.
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101(1):130–138.
   PubMed Web of Science ®Google Scholar
• Brown-elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of mycobacterium avium complex with proposed mic breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389–3394.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv. 2008;21(3):245–254.
   PubMed Web of Science ®Google Scholar
• US FDA. Arikayce® (amikacin liposome inhalation suspension): US prescribing information. (2020)
   Google Scholar
• Malinin V, Neville M, Eagle G, et al. Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats. Antimicrob Agents Chemother. 2016;60(11):6540–6549.
   PubMed Web of Science ®Google Scholar
• Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22(2):131–138.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Bucke W, Leitzke S, et al. Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings. Int J Med Sci. 1996;284(2):218–231.
   Google Scholar
• NDA/BLA Multi-Disciplinary Review and Evaluation-NDA 2073 56. (2018). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207356Orig1s000MultidisciplineR.pdf; Access data:19/08/2020
   Google Scholar
• Griffin DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT). Am J Respir Crit Care Med. 2018;198:1559–1569.
   PubMed Web of Science ®Google Scholar
• Rubino CM, Onufrak N, Griffith DE, et al. KLW.pharmacokinetic (PK) evaluation of amikacin liposome inhalation suspension (ALIS) in patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease. Am J Respir Crit Care Med. 2019;199:A2654.
   Web of Science ®Google Scholar
• Fielding RM, Ramilla O. Lewis LM-M. altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low clearance liposomes (MiKasome). Pharm Res. 1998;15(11):1775–1781.
   PubMed Web of Science ®Google Scholar
• Fielding RM, Moon-mcdermott L, Lewis RO, et al. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob Agents Chemother. 1999;43(3):503–509.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Grif DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in non-tuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017; 195(6): 814–823.
   PubMed Web of Science ®Google Scholar
• Swenson C, Lapinel NC, Ali J. Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension : results from a patient survey. Open Forum Infect Dis. 2019;7(4):1–4.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Moon SM, Park HY, Kim S, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60(11):6758–6765.
   PubMed Web of Science ®Google Scholar
• Kadota T, Matsui H, Hirose T, et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis. 2016;16(31):1–8:
   Google Scholar
• Koh W-J, Kim YH, Kwon OJ, et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci. 2008;23(3):397–401. 20;
   PubMed Web of Science ®Google Scholar
• Kwon YS, Koh WJ, Daley CL. Treatment of mycobacterium avium complex pulmonary disease. Tuberc Respir Dis (Seoul). 2019;82(1):15–26.
   PubMed Web of Science ®Google Scholar